WASHINGTON — The agreement between Pfizer and the Trump administration to lower drug prices has sent other companies scrambling to make a deal.
Several major pharmaceutical firms that received letters from President Trump demanding lower prices have been hustling to show progress, with some hoping to announce a deal with the White House as soon as this week, according to five Washington representatives and lobbyists for the companies, granted anonymity to speak about private deliberations.
“They have to now,” said one lobbyist of their clients’ thinking, noting the “anger” with Pfizer for effectively adding to their pressure to come to an agreement with the administration.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
